P602: CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm
ECCO '19 Copenhagen
2019
P603: Paediatric onset inflammatory bowel disease is not associated with more disability compared with adult onset disease
ECCO '19 Copenhagen
2019
P604: Biologics with or without a combination with 5-ASA in ulcerative colitis: frequency of usage and effect on the course of disease in the Swiss IBD-Cohort study
ECCO '19 Copenhagen
2019
P605: CRP reduction rate following initiation of anti-tumour necrosis factor-α induction therapy predicts secondary loss of response in patients with Crohn's disease
ECCO '19 Copenhagen
2019
P606: Steroid use in inflammatory bowel disease patients on biological therapy in Montenegro
ECCO '19 Copenhagen
2019
P607: Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P608: Crohn’s disease patients with high baseline symptoms achieve clinical remission more rapidly with Budesonide than with Mesalazine
ECCO '19 Copenhagen
2019
P609: Handsewn anastomosis after ileo-colic resection for Crohn’s disease: a lost art?
ECCO '19 Copenhagen
2019
P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary
ECCO '19 Copenhagen
2019
P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study
ECCO '19 Copenhagen
2019
P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study
ECCO '19 Copenhagen
2019
P613: Tacrolimus as rescue therapy for steroid-dependent/steroid refractory ulcerative colitis: experience from tertiary referral centre
ECCO '19 Copenhagen
2019
P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P615: Rescue infliximab for acute severe colitis: a single-centre experience
ECCO '19 Copenhagen
2019
P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres
ECCO '19 Copenhagen
2019
P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics
ECCO '19 Copenhagen
2019
P618: Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study
ECCO '19 Copenhagen
2019
P619: Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission
ECCO '19 Copenhagen
2019